Cipla Ltd, a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients, is delighted to announce the appointment of Mr. Peter Lankau as an independent director on its board with effect from 10th January 2017.
Mr. Lankau has graduated with Bachelors of Science in Biology from the State University of New York at Albany, USA. He has over 30 years of management experience in developing and commercializing pharmaceutical products.
Mr. Lankau is currently a principal of Lankau Consulting LLC. He was previously Executive Chairman of the Board for Nautilus Neurosciences, Inc., Chairman & CEO of Logical Therapeutics, Inc. and President & CEO of Endo Pharmaceuticals Inc. Prior to Endo Pharmaceuticals Inc., he was VP, Sales and Marketing for Alpharma, Inc. He began his pharmaceutical career with Rhone-Poulenc Rorer, Inc. (now Sanofi).
Mr. Lankau currently serves on the Board of Directors of ANI Pharmaceuticals, Inc. and Phosphagenics Limited and also on the Board of Advisors of Orchard Venture Partners, a life sciences venture capital firm.
Welcoming his appointment as an independent director, Dr. Y. K. Hamied, Non-Executive Chairman, Cipla Limited said: "Mr. Lankau brings with him a deep understanding of the US Pharmaceutical market that will help us steer the future thinking of our Company for this focus market."
Mr. Peter Lankau said: "I am delighted to join the Cipla Board, a Company that has had such an inspiring history and bold dreams for its future."
Shares of CIPLA LTD. was last trading in BSE at Rs.576.8 as compared to the previous close of Rs. 582.15. The total number of shares traded during the day was 84490 in over 1478 trades.
The stock hit an intraday high of Rs. 588.45 and intraday low of 575.5. The net turnover during the day was Rs. 49143126.